3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Pancreatic Neoplasms
5
Melanoma
4
Glioblastoma
4
Carcinoma
4
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Neoplasms
2
Fibrolamellar hepatocellular carcinoma
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Merkel Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Interventions
Temozolomide
15
Radiotherapy
10
Radiation
8
Magnetic Resonance Spectroscopy
7
pembrolizumab
5
Specimen Handling
5
Ipilimumab
3
atezolizumab
2
Photons
2
Nivolumab
2
Biopsy
2
veliparib
1
selinexor
1
sargramostim
1
plerixafor
1
peposertib
1
pazopanib
1
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
montanide ISA 51
1
liposomal doxorubicin
1
gosha-jinki-gan
1
fluorodopa F 18
1
ferric pyrophosphate
1
efineptakin alfa
1
cemiplimab
1
cabozantinib
1
balstilimab
1
abexinostat
1
X-Rays
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gliosarcoma
×
poly ICLC
×
1 year
×
Clear all
No trials found.